FFAR2/3: free fatty acid receptor 2/3
Originally developed to treat type 2 diabetes, these agonists have been clinically proven to promote significant weight loss by mimicking the effects of the GLP-1 hormone, which plays a crucial role in regulating appetite and blood sugar levels
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardio-vascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Choosing the Right Option Factors to Consider When deciding between Semaglutide and Tirzepatide, several factors should be considered, including the individuals medical history, specific weight loss goals, common side effect issues, and cost
Contact us for a consultation about semaglutide weight loss treatments
For other AOMs, it is suggested to stop treatment if weight loss of more than 5% has not been achieved after 12 weeks of treatment [9]